Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
Pfizer Consumer relies on Alacer addition; Latin America strong for Bayer OTCs; Allegra Japan launch drives Sanofi OTC growth; Herbalife overcomes investor “noise”; Rx slide offsets Merck OTC gains.
You may also be interested in...
Pfizer Posts Weak First Quarter As It Continues To Mull Over A Split
The Big Pharma disappoints investors with a weak first quarter and a failure to come to any decisions about the future structuring of the company. Meanwhile, the company made little progress of note during the quarter.
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: